Swiss drugmaker Lonza projects robust growth, anticipating 11-12% sales growth by 2026. The company also expects its core EBITDA margin to exceed 32%, signaling continued financial health. This positive outlook follows a strong 2025, where Lonza reported 21.7% sales growth in constant exchange rates, reaching 6.5 billion Swiss francs.

Lonza's strategy focuses on expanding its manufacturing network and securing new contracts. The company invested heavily in capital expenditures during 2025, reaching 1.3 billion francs, which reinforces its commitment to meet growing demand. The board proposed a 25% dividend increase, subject to approval at the annual general meeting in May 2026.

Despite anticipating a 2% foreign exchange headwind in 2026, Lonza remains optimistic, aiming for stronger sales growth in the first half of the year. The company's CEO emphasized the resilience of its business model. Lonza is a leading player in the contract development and manufacturing organization (CDMO) industry, which is experiencing sustained growth.

This positive forecast is encouraging for investors, particularly given the volatility in the current market. Lonza's diversified operations and expanding global footprint position it well to navigate economic uncertainties. The company's growth in areas like Integrated Biologics and Advanced Synthesis demonstrate its ability to adapt to changing market dynamics.